A citation-based method for searching scientific literature

Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull, George Capuano, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Tao Sun, David C Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Norman Rosenthal, Barry M Brenner, Vlado Perkovic. Circulation 2019
Times Cited: 101



Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews, Bruce Neal. Lancet Diabetes Endocrinol 2018
Times Cited: 239




List of shared articles



Times cited


Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Jaime Blais, Qiang Li, Meg J Jardine,[...]. Am J Kidney Dis 2021
5

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
Jie Yu, Zien Zhou, Kenneth W Mahaffey, David R Matthews, Brendon L Neuen, Hiddo J L Heerspink, Meg J Jardine, JingWei Li, Vlado Perkovic, Bruce Neal,[...]. Int J Cardiol 2021
3

Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
Chin Meng Khoo, Chaicharn Deerochanawong, Siew Pheng Chan, Bien Matawaran, Wayne Huey-Herng Sheu, Juliana Chan, Ambrish Mithal, Andrea Luk, Ketut Suastika, Kun-Ho Yoon,[...]. Diabetes Obes Metab 2021
2

Canagliflozin: metabolic, cardiovascular and renal protection.
Vivencio Barrios, Carlos Escobar. Future Cardiol 2021
1

Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.
Ricardo Fontes-Carvalho, Diogo Santos-Ferreira, Itamar Raz, Nikolaus Marx, Frank Ruschitzka, Francesco Cosentino. Eur J Prev Cardiol 2021
1

Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
Takashi Kadowaki, Fumiko Yamamoto, Yusuke Taneda, Yusuke Naito, Douglas Clark, Søren S Lund, Tomoo Okamura, Kohei Kaku. Expert Opin Drug Saf 2021
0


Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
0

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Thomas A Zelniker, Itamar Raz, Ofri Mosenzon, Jamie P Dwyer, Hiddo H J L Heerspink, Avivit Cahn, Erica L Goodrich, Kyungah Im, Deepak L Bhatt, Lawrence A Leiter,[...]. JAMA Cardiol 2021
0

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin,[...]. Eur J Heart Fail 2021
1

How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR.
Clara García-Carro, Ander Vergara, Sheila Bermejo, María A Azancot, Ana I Sánchez-Fructuoso, M Dolores Sánchez de la Nieta, Irene Agraz, María José Soler. J Clin Med 2021
0


Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
Naoki Kashihara, Kengo Kidokoro, Eiichiro Kanda. Curr Opin Nephrol Hypertens 2020
7


Sodium-glucose linked transporter-2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk.
Guntram Schernthaner, Per-Henrik Groop, Philip A Kalra, Claudio Ronco, Maarten W Taal. Diabetes Obes Metab 2020
4




Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.
Shrita Patel, Anne Hickman, Robert Frederich, Susan Johnson, Susan Huyck, James P Mancuso, Ira Gantz, Steven G Terra. Diabetes Ther 2020
9

Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis.
Mei Qiu, Shu-Yan Liu, Jin-Song Gu, Kai-Kai Li, Ling-Lin Li, Liang-Liang Ding. Endocrine 2020
2


2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu,[...]. J Chin Med Assoc 2020
0

Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care.
Subodh Verma, Eric Klug, Viacheslav Y Mareev, Zhanna D Kobalava, Kim A Connelly, Mustafa Arici, Otávio Berwanger, Anwar Santoso, Roopa Mehta, Gus Meglis,[...]. Curr Opin Cardiol 2020
0

RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020.
Rajeev Chawla, S V Madhu, B M Makkar, Sujoy Ghosh, Banshi Saboo, Sanjay Kalra. Indian J Endocrinol Metab 2020
13

SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies.
Mei Qiu, Liang-Liang Ding, Miao Zhang, Jin-Hao Lin, Jin-Song Gu, Xian Zhou, Ying-Xi Tang, Xu-Bin Wei, Shu-Yan Liu. Pharmacol Res 2020
3

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.
Janani Rangaswami, Vivek Bhalla, Ian H de Boer, Alexander Staruschenko, Johanna A Sharp, Radhika Rajgopal Singh, Kevin Bryan Lo, Katherine Tuttle, Muthiah Vaduganathan, Hector Ventura,[...]. Circulation 2020
25

Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.
Megumi Oshima, Brendon L Neuen, JingWei Li, Vlado Perkovic, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Adeera Levin, Kenneth W Mahaffey,[...]. J Am Soc Nephrol 2020
12


Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations.
Mohamed Hassan Elnaem, Noha O Mansour, Abdulrahman Fata Nahas, Mohamed A Baraka, Ramadan Elkalmi, Ejaz Cheema. Int J Gen Med 2020
1